Huntington's disease (HD) reflects dominant consequences of a CAG repeat expansion mutation in HTT. Expanded CAG repeat size is the primary determinant of age at onset and age at death in HD. Although HD pathogenesis is driven by the expanded CAG repeat, whether the mutation influences the expression levels of mRNA and protein from the disease allele is not clear due to the lack of sensitive allele-specific quantification methods and the presence of confounding factors. To determine the impact of CAG expansion at the molecular level, we have developed novel allele-specific HTT mRNA and protein quantification methods based on principles of multiplex ligation-dependent probe amplification and targeted MS/MS parallel reaction monitoring, respectively. These assays, exhibiting high levels of specificity and sensitivity, were designed to distinguish allelic products based upon expressed polymorphic variants in HTT, including rs149 109 767. To control for other cishaplotype variations, we applied allele-specific quantification assays to a panel of HD lymphoblastoid cell lines, each carrying the major European disease haplotype (i.e. hap.01) on the mutant chromosome. We found that steady state levels of HTT mRNA and protein were not associated with expanded CAG repeat length. Rather, the products of mutant and normal alleles, both mRNA and protein, were balanced, thereby arguing that a cis-regulatory effect of the expanded CAG repeat is not a critical component of the underlying mechanism of HD. These robust allele-specific assays could prove valuable for monitoring the impact of allele-specific gene silencing strategies currently being explored as therapeutic interventions in HD. †
Introduction
Huntington's disease (HD) (OMIM #143 100) (1,2) is a dominantly inherited neurodegenerative disorder involving clinical manifestations in motor, cognitive and psychiatric domains (3) (4) (5) (6) and premature death (7) (8) (9) . The single genetic cause of HD is a CAG trinucleotide repeat expanded to >35 units in the first exon of HTT (1), encoding the large huntingtin protein (HTT), which has potentially multiple functions and shows ubiquitous expression (2, 3, (10) (11) (12) (13) . The size of the HTT CAG repeat largely determines age at onset of neurological symptoms in a completely dominant fashion: the longer the CAG repeat, the earlier age at onset of clinical signs (7, 9, (14) (15) (16) . The mechanism that triggers HD pathogenesis is thought to involve a gain-of-function based upon 1) the true dominant inheritance of the disorder (1); 2) the evidence for putative HTT-reducing mutations causing a recessive Rett syndrome-like neurodevelopmental disorder in humans (17) ; 3) the lethality in mouse embryos of complete loss of Htt (18) (19) (20) ; 4) the preservation in mutant HTT of biochemical and functional characteristics of the normal protein (13, (21) (22) (23) ; and 5) modulatory functional effects of the expanded CAG repeat within both the normal and expanded CAG repeat lengths (24) . This dominant gain-of-function becomes progressively stronger as the CAG repeat size increases, resulting in an accelerated rate of pathogenesis and earlier development of disease symptoms. However, although the gain-offunction mechanism most likely acts through a product of HTT, it is not clear whether the mutation has a direct impact on the levels of expression of either HTT mRNA or protein product, due to the lack of sensitive allele-specific quantification methods. Therefore, we developed novel allele-specific quantification assays to directly test whether expanded CAG repeats play a cis role in determining the levels of HTT products (mRNA and protein) in human HD cells.
Results
No apparent association between CAG repeat sizes and total HTT mRNA/huntingtin protein levels Initially, we tested in a non-allele-specific manner for a continuous influence of HTT CAG repeat length on the expression levels of endogenous HTT mRNA and protein. Total HTT mRNA expression levels determined by microarray were not correlated with the CAG repeat lengths in 107 lymphoblast cell lines (LCLs) derived from HD subjects and normal controls (25) . Similarly, total HTT mRNA levels in peripheral blood (Gene Expression Omnibus, GSE8762) (26) and post-mortem brains from HD subjects and controls (Gene Expression Omnibus, GSE3790) (27) determined by microarrays were not associated with expanded (or longer) CAG, normal (or shorter) CAG, or the sum of the two CAG alleles (Supplementary Material, Fig. S1 and Tables S1, S2). To confirm these observations using independent measurement technologies, we profiled mRNA and protein expression levels in a panel of 24 LCLs by RNAseq and quantitative proteomics, respectively. In analyses focusing on HTT as shown in Figure 1 , neither the RNAseq method nor iTRAQ proteomics technology revealed significant associations between the levels of either of the HTT products (mRNA and protein) and longer CAG (A and D), shorter CAG (B and E) or the sum of the CAGs (C and F).
Allele-specific quantification of HTT mRNA
The lack of significant correlation between CAG repeat length and the steady-state HTT expression levels in these microarray, RNAseq and quantitative proteomics data suggested that CAG repeat size does not impact on the levels of HTT products. However, all of these measurements were based on total HTT levels comprising the combined production from both alleles determined in a non-allele-specific manner. Therefore, they were insensitive to potential cis effects of the expanded CAG repeat specifically on HTT expression from the mutant allele. In theory, the distinction between the normal and expanded CAG repeat itself could be detected in RNAseq analysis for allelespecific assessment of expression levels. However, the efficiency of reverse transcription in this region of HTT mRNA may be influenced by RNA secondary structure, resulting in variable and far lower recovery of sequence relative to the rest of the mRNA (data not shown). Consequently, assessments based upon this segment risk skewing determination of the mutant:normal expression ratio. Although RNAseq analysis did in some cases reveal sequence variants in other regions of HTT not vulnerable to this bias, the panel of 24 LCLs represented multiple HTT haplotypes that were not optimally assorted for such allele-specific expression analysis (data not shown).
To directly test the cis effect of the CAG repeat on HTT expression levels, we set out to develop an allele-specific HTT mRNA quantification method using exon variants that are different between HD disease chromosomes and their normal counterparts. Through comprehensive haplotype analysis, we have found that the hap.01 haplotype accounts for approximately 50% of disease chromosomes in HD subjects with European ancestry (28) . Independent HD families inheriting this haplotype have almost identical sequences across HTT, including exon, intron and promotor regions (29) . To directly test the cis effect of the expanded CAG repeat on HTT expression levels without the potential confound of expression differences caused by other sequence variants in HTT, we therefore developed an allele-specific HTT mRNA quantification method using exonic sequence variations that mark the HD hap.01 haplotype. Full genomic sequence of such chromosomes identified three exonic variants, rs149 109 767 (previously delta2642), rs362 307, and rs115 335 747, whose alternative (i.e. non-reference) alleles are present on the hap.01 haplotype (29) but absent from most other HTT haplotypes (Supplementary Material, Fig. S2 ), permitting direct assessment of mutant and normal allelic expression independently and simultaneously.
The allele-specific HTT mRNA quantification assay employed specific sets of multiplex ligation-dependent probe amplification (MLPA) probes to detect: 1) the three variant sites in an allele-specific manner, 2) four different non-variant HTT sites and 3) two control genes (GUSB and PARN) (Table S3) in reversetranscription (RT)-produced cDNA. To distinguish alleles at a given variant site, we designed a set of three probes with different sizes of stuffer sequences; a left probe representing the alternative allele found in hap.01 (i.e. alternative allele probe), a left probe representing the reference allele found in most of other haplotypes (i.e. reference allele probe), and a single right probe with 5 0 -phosphorylation (i.e. common probe; Table S3 ).
When a left probe hybridizes perfectly to its corresponding mutant or normal HTT allele-derived cDNA, it lies immediately adjacent to the common right probe, enabling the two to be joined by DNA ligase, forming a single contiguous probe (Supplementary Material, Fig. S3 ). The allelic products generated by incorporation of each left probe differ due to the different length of additional stuffer sequence in each case (Table S3 , lower cases). Ligated probes are then PCR amplified and separated for detection by a sequencing machine, permitting quantification of each allele independently. Benchmark tests to evaluate the performance of the HTT quantitative reverse transcription-MLPA (qRT-MLPA) assay indicated 1) high allele specificity ( Fig. 2A-2C Fig. 2D-2F ).
Having confirmed the excellent performance of the qRT-MLPA assay, we next tested the relationship between CAG repeat size and HTT mRNA expression levels in an allele-specific manner. We chose 29 HD LCL lines carrying expanded CAG repeats of different size on the major European hap.01 haplotype (28) . In these cell lines, normal CAG repeats are on diverse nonhap.01 haplotypes (data not shown). Based on summarized data from four independent qRT-MLPA assays using two sets of independent RNA samples from these 29 LCLs carrying the same disease haplotype, the size of the CAG expansion showed no relationship with variation in expression of the mutant HTT mRNA (Fig. 2G) . Nor was there an association between the length of the normal CAG allele and its product (Fig. 2H) . However, the levels of expanded and normal HTT mRNA showed a strong positive correlation with each other, indicating that HTT allelic expression is balanced in individual LCLs. Since total HTT mRNA steady state levels vary by cell line independently of the expanded CAG repeat (Fig. 2I) , our data argue against a cis role for the mutation in influencing steady-state mRNA expression levels, either through transcription, processing or stability.
Allele-specific quantification of huntingtin protein
We next addressed the question of whether the mutation exerts a direct effect on huntingtin protein levels. Initially, we determined total huntingtin protein levels in LCLs using an ELISAbased Meso Scale Discovery (MSD) electrochemiluminescence assay platform (30) , and subsequently tested the potential correlation of these with total HTT mRNA levels and CAG repeat sizes. Huntingtin protein levels were significantly correlated with total HTT mRNA levels (Supplementary Material, Fig. S8A ), but variation in huntingtin protein levels was not explained by CAG repeat size (Supplementary Material, Fig. S8B and S8C ). However, since the MSD assay used for this study was not allele-specific, it may not have been sufficiently sensitive to detect an effect of the expanded CAG repeat on its allelic product, whether through translation and/or protein stability. A variety of antibody-based methods have been used to distinguish mutant and normal huntingtin protein, such as SDS-PAGE immunoblot, time-resolved fluorescence resonance energy transfer (31) , and MSD (30), but these have a variety of technical limitations, not the least of which are effects of the CAGencoded polyglutamine tract on conformation and immunoreactivity of huntingtin protein, which can confound accurate quantification (30, 32) . Therefore, we developed an allele-specific method to quantify huntingtin protein levels using a parallel reaction monitoring (PRM)-based targeted mass spectrometry technique that does not depend on antibodies.
We designed a PRM assay to detect the tryptic peptides involving the codon indel, rs149109767 that was used for our allele-specific qRT-MLPA assay. The major European HD haplotype, hap.01, encodes five consecutive glutamic acid residues (5E), while most other haplotypes encode six glutamic acids (6E) (28) , allowing us to measure mutant (5E including tryptic peptide) and normal huntingtin (6E including tryptic peptide) levels independently in cells carrying hap.01 disease haplotype. First, to characterize the fragmentation patterns of target peptides in Mutant HTT mRNA levels (p-val, 3.7E-9)
Normal HTT mRNA levels carry reference alleles. Allele-specific probes generated expected allele signals for alternative alleles for hap.01 (red arrows) and reference alleles (green arrows) for other haplotypes, respectively, supporting its allele-specificity. Although, a small level of non-specific peak for rs149 109 767 alternative allele was generated (B, black filled circle), we reasoned that that non-specific peak in samples with actual hap.01 haplotypes would be yet smaller, not strongly affecting analysis results. Non-allele-specific probes for total HTT (black arrows) and control genes (orange arrows) yielded signals regardless of haplotypes present. green circles, GUSB) were relatively constant regardless of the mixing ratios as expected. (G-I) 4 sets of LCL RNA samples with hap.01 haplotypes were used for MLPA assay to test cis association between CAG and HTT mRNA expression levels. Relative expression levels of expanded and normal HTT mRNA determined by rs149 109 767 (Y-axis) were modeled as a function of expanded (G) and normal CAG repeat size (H) using linear regression analysis, respectively. P-values are provided next to the X-axis titles. CAG was also not significant in models based on a non-averaged individual data set (data not shown). In addition, averaged expression levels of expanded (X-axis) were modeled by normal HTT mRNA levels (Y-axis) to judge any allelic imbalance. Highly significant regression analysis P-value supported the lack of strong allele-imbalance.
the mass spectra, synthetic tryptic peptides with 5E or 6E were analyzed by mass spectrometry (MS 3A and 3B ), indicating the capacity of the assay to specifically detect the endogenous HTT allelic products. Total huntingtin protein levels in these cell lines were also detected by three representative peptides (i.e. pan peptides) derived from the N-terminal, middle and C-terminal regions of huntingtin protein (Fig.  3C) . PRM assays using different amounts of lysate generated signals that were proportional to the inputs (Supplementary Material, Fig. S10 ), and samples mixed with lysates of two different haplotypes yielded PRM signals that well represented the mixing ratios ( Fig. 3D and 3E ). Together, these results indicated that our huntingtin PRM assay is allele-specific with robust assay linearity and sensitivity. We next tested directly the relationship between CAG repeat size and steady-state huntingtin protein levels in an allelespecific manner. We used 28 of the HD subject-derived LCLs that were used in our qRT-MLPA assay, all of which were heterozygous for rs149 109 767 and therefore expressed 5E and 6E huntingtin as mutant and normal allelic products, respectively. Consistent with the results of qRT-MLPA assay, the expanded CAG repeat size did not explain variation in the level of mutant huntingtin protein (Fig. 3F) . Neither did the normal CAG repeat length correlate with the level of normal huntingtin protein expression (Fig. 3G) . However, as with HTT mRNA, the levels of mutant and normal huntingtin protein were significantly correlated with each other, again arguing against a cis role for the CAG repeat on influencing HTT expression, this time at the protein level (Fig. 3H) .
Discussion
In the literature, depending on measurement methods and tissue sources, allelic expression patterns of mutant and normal HTT in HD have been inconsistent. One report of an allelespecific qRT-PCR assay aimed at detecting SNP alleles in postmortem cortex and striatum samples of HD subjects showed increased steady-state levels of mutant compared to normal HTT mRNA, potentially due to increased transcription of the mutant HTT mRNA or to accumulation of mutant HTT mRNA (33) . Interestingly, allelic differences were associated with pathological grade, but were not seen in a spared region at early stage of HD (i.e. cerebellum), suggesting that the level of pathology in tissues might impact the mutant:normal allelic expression ratio (33) . By contrast, another analysis of postmortem HD brain tissues found a decrease in mutant HTT mRNA relative to the normal allelic product, but no difference in the levels of mutant and normal huntingtin protein, except in juvenile onset where the former protein was reduced (34) . In other studies, with small numbers of samples, HD patient-derived fibroblasts (34) and monocytes (35) expressed relatively similar amounts of mutant and normal HTT mRNA, while antibody-based quantification of huntingtin protein has also suggested that the level of the mutant protein is robustly reduced compared to normal huntingtin in HD lymphoblasts (36) . Recently, it has been suggested that a SNP variation (rs13102260) in the promotor region of HTT acts as a cis-regulatory variant to modulate the expression of HTT and thereby modify the onset of HD (37) . However, genome-wide association analysis did not implicate this SNP, or any other variation at the HTT locus as a genome-wide significant modifier of the age at onset of HD motor signs (38, 39) . Regardless of its clinical impact, if variation at this site modifies HTT expression, it could contribute to the cause of observations of allelic imbalance being mistakenly attributed to the expanded CAG repeat. To avoid such potential confounds in our specific test of a potential cis-effect of the expanded CAG on HTT expression, we analyzed only human cells that carry the mutation on the hap.01 haplotype, which is the ancestral founder haplotype shared by the disease chromosomes in almost half of all European HD subjects (28, 29) . This haplotype carries the reference allele at rs13 102 260, and therefore variation in the levels of mutant HTT mRNA and protein in our study were not due to other variants in cis-regulator sequences on the disease chromosome. By applying newly developed allele-specific HTT quantification assays to a panel of human HD cells carrying the major European HTT haplotype with mostly adult onset CAG repeats, we have determined that the expanded HTT CAG repeat does not exert a direct effect on the steady-state levels of mutant HTT mRNA or of huntingtin protein, suggesting that such an effect is not a central player in the HD process, given a strong negative correlation between CAG repeat size and age at onset. Interestingly, while HTT mRNA and huntingtin protein levels were generally correlated, they showed wide variability across individuals. This variability was also not related to CAG repeat size, indicating the absence of any strong indirect effect of the mutation on HTT expression in these cells. Although our data strongly support the lack of allelic imbalance in cells carrying adult onset CAG repeats on the major European disease haplotype, the impacts of CAG repeat sizes on HTT expression levels in human brains remain unknown since allele-specific quantification assays correcting for confounding variables (e.g. pathological grades and haplotypes) have not been performed due to various technical difficulties. We attempted to gain indirect insights into the CAG-HTT level relationships in brains by using neural progenitor cells (NPC), locally generated from HD induced pluripotent stem (iPS) cell lines. Due to the limited availability of hap.01 NPC lines, we analyzed HD NPC lines carrying hap.03 as the mutant chromosomes (the third most frequent disease chromosome in HD with European ancestry) (28). Although not sufficiently powered to detect small effects, RNAseq analysis did not reveal robust correlation between total HTT mRNA expression levels and CAG repeat sizes (Supplementary Material, Fig. S11 ), implying independency between two parameters.
Our quantification assays should facilitate a search for the sources of this variability, which could be genetic or environmental, but in either instance might provide clues to novel mechanisms for indirectly modulating mutant HTT expression. Currently, HD therapeutic strategies designed to down-regulate mutant HTT expression are based on a variety of gene targeting/ gene silencing technologies and, while promising, have yet to be proved in humans. Our data imply that the strong inverse relationship between CAG repeat size and age at onset is not due to reduction of HTT expression levels as a function of CAG size. Rather, these findings provide a mechanistic explanation supporting beneficial outcomes of therapeutic targeting seen in mutant allele-specific or non-allele-specific HTT lowering in model systems (40) . Similarly, our results suggest that clinical efficacy of mutant HTT-specific lowering that seen in mice would replicate in humans, facilitating gene targeting strategies. Our robust allele-specific assays should prove valuable for assessing the efficacy and consequences of any therapeutic strategies that either directly or indirectly target HTT mRNA and/or huntingtin protein expression. Data presented here directly support the value of novel allele-specific assays in preclinical studies. Further validation of the specificity and sensitivity of our assays in blood and cerebrospinal fluid samples from HD subjects will greatly augment their utilities in clinical trials as well. Consequently, they offer the promise of accelerating the definition and testing of an effective treatment for this devastating disorder.
Materials and Methods

Microarray data analysis
Raw microarray gene expression data of blood and post mortem brain samples from HD subjects and controls were obtained from the Gene Expression Omnibus (GSE8762 and GSE3790, respectively), and subsequently normalized by gcRMA (version 2.10). Quality control analysis and outlier detection was done by Figure 3 . Lack of cis association between CAG repeat length and huntingtin expression levels. (A-C) Allele-specific or total HTT protein expression levels of LCL lines carrying hap.01/hap.01 (5E/5E), hap.02/hap.other (6E/6E) and hap.01/hap.08 (5E/6E) were determined by PRM assay. Three fragment ions derived from triply charged 5E peptide or 6E peptide precursor were extracted and summed to represent the 5E (A) or 6E peptide abundance (B), respectively. In addition, three pan tryptic peptides were selected and the average three ion intensities of these peptides used to represent total huntingtin abundance (C). Data represent mean of three experiments (technical replica) 6 standard deviation (SD). (D and E) Two LCL lines carrying huntingtin with 6E/6E and 5E/5E were mixed in different ratios for PRM assays to evaluate its sensitivity. The bar plots show normalized levels of 5E peptide (D) or 6E peptide abundances (E). Data represent mean of three experiments (technical replicates) 6 SD. (F-H) HTT protein expression levels originated from a chromosome with expanded CAG represented by 5E peptide abundance were plotted against the expanded CAG repeat lengths for linear regression analysis (F). HTT protein expression levels from the normal allele, determined by 6E peptide, were plotted against the normal CAG repeat lengths (G). Each circle indicates an average value of an independent LCL. P-value of a given model is provided next to the X-axis title. CAG was not significant in a model based on non-averaged individual data set (data not shown). The scatter plot displays the relationship between the expanded HTT protein expression levels (X-axis; 5E peptide abundance) and the normal HTT protein expression levels (Y-axis; 6E peptide abundance) (H).
principal components analysis (PCA) using all probes. Then, HTT mRNA expression levels were modeled as a function of the size of 1) expanded (or longer) CAG repeat, 2) normal (or shorter) CAG repeat or 3) the sum of two alleles (linear regression analysis) to determine the influence of CAG repeat size.
RNAseq RNA profiling and iTRAQ protein profiling of HD lymphoblastoid cell lines A panel of 24 EBV-transformed lymphoblastoid cell lines (LCLs) from HD subjects (17 lines) and controls (7 lines) were grown in a standard culture condition (25) for RNA transcriptome profiling by RNAseq and protein profiling by iTRAQ (isobaric tags for relative and absolute quantification) method (41, 42) . For RNAseq analysis, Illumina sequence reads (50-bp paired end) were aligned and processed by GSNP (http://research-pub.gene. com/gmap/) and Cuflinks programs (http://cole-trapnell-lab. github.io/cufflinks/) for subsequent generation of expression level data in FPKM units. For iTRAQ protein profiling, protein extracts were labeled with TMT6 reagents followed by fractionation by Strong-Cation-Exchange HPLC and LC-MS/MS (Proteome Sciences R&D GmbH & Co. KG). Huntingtin protein expression was expressed as a relative level compared to a reference sample representing the pool of all 24 samples. Then, technical duplicate measurements were averaged to generate a single representative expression value for each sample.
Development of allele-specific HTT mRNA quantification method
Three DNA variations that can distinguish the hap.01 haplotype from other haplotypes were selected to design MLPA probes. Alternative alleles of those DNA variants are present on hap.01, while reference alleles are present on most other haplotypes. Sequences of probes to detect alternative alleles or reference alleles on the HTT cDNA and housekeeping genes are described in Supplementary Material, Table S3 . Total RNA samples were converted to cDNA using random hexamer reverse transcription (RT) primer. Then, MLPA probes were hybridized for subsequent ligation, PCR amplification (https://www.mlpa.com/), and fragment analysis by ABI3730 DNA analyzer according to the manufacturer's protocol.
We aimed to achieve allele specificity using a pair of probes designed to be ligated only in the presence of the target SNP allele on the cDNA. In order to test allele specificity of the assay, three LCL RNA samples with different haplotype compositions were used; a HD subject with diplotype hap.01/hap.01 (heterozygous HD; expanded CAG on hap.01 and normal CAG on hap.01), a normal individual with hap.02/hap.other carrying reference alleles for all 3 sites, and a HD subject with hap.01/hap.08 (heterozygous HD; expanded CAG on hap.01 and normal CAG on hap.08). For example, if a sample has two hap.01 haplotypes, MLPA signals for an alternative allele would be generated because hybridization of alternative allele probe and common probe will lead to ligation ( Fig. 2A; peak marked by red arrows) . If a sample carries two copies of non-hap.01 haplotypes, only reference alleles at the three variant sites ( Fig. 2B ; peaks marked by green arrows) would generate signals. If a sample carries one copy of hap.01 and one copy of non-hap.01, an allele-specific probe pair would generate both alternative allele and reference allele peaks marked by either red and green arrows, respectively (Fig. 2C) . MLPA peaks for total HTT (black arrows) and housekeeping genes (orange) are not allele-specific, and therefore MLPA signals would be generated regardless of haplotypes. These predictions were tested using total RNA (150 ng) from three LCLs carrying either hap.01/hap.01 (A), hap.02/hap.other (B) or hap.01/hap.08 haplotypes (C) (30 PCR cycles). Alternative allele probes for rs149 109 767 generated small signals in the absence of hap.01 haplotype (Fig. 2B, black circle) . Since rs149 109 767 is an indel polymorphism involving repeats, the non-specific signal might have been generated due to partial hybridization between cDNA template with reference allele and alternative allele probe. However, we predict the levels of nonspecific signal would be very small if a sample has an alternative allele for rs149 109 767 because potential partial hybridization between alternative allele probe and reference allele cDNA would be minimal due to competition between favorable correct hybridization and unfavorable incorrect hybridization. The linearity of the assay was also tested by altering the input amounts of total RNA (a sample with hap.01/hap.08 was used; Supplementary Material, Fig. S4 ). Briefly, 10-250 ng of total RNA samples from a HD LCL with hap.01/hap.08 haplotypes were subject to RT-MLA assay by either 25, 30 or 35 PCR cycles. The SNP rs149109767 was used to represent allele-specific HTT mRNA levels. Lastly, the sensitivity of the HTT qRT-MLPA assay was determined by mixing two RNA samples carrying different haplotypes in different ratios (Fig. 2 ). In mixed samples (100 ng total RNA), we assessed how well MLPA assay results quantitatively reflected different levels of alternative and reference alleles. Analysis results were summarized for rs149 109 767 (Fig.  2D) , total HTT signals (Fig. 2E ) and control genes ( Fig. 2F ; PARN and GUSB).
Association analysis between CAG repeat size and HTT mRNA levels
We determined HTT mRNA expression levels in an allelespecific manner using 29 HD LCLs to test an association between CAG repeat sizes and HTT mRNA expression levels. All these lines carry hap.01 as the disease chromosome, eliminating the possibility of cis-effects other than the CAG repeat. The ranges of expanded and normal CAGs in this HD LCL panel were 39-60 and 9-26, respectively. Two sets of total RNA samples were independently obtained from this LCL panel (Set A and B), and two independent HTT qRT-MLPA assays were performed for each set of RNA samples (Assay 1 and 2), generating total four measurements for each LCL line. For data normalization, two different control genes (PARN and GUSB) were used. Briefly, the area under the curve (AUC) of peaks was divided by that of either PARN or GUSB, generating expression values of HTT mRNA relative to control mRNAs for a given sample. Then, expression levels of expanded, normal and total HTT mRNA were divided by those of the sample with the smallest CAG repeat (i.e. reference sample) to calculate relative expression levels. Because the normalized data from two different control genes were highly correlated (data not shown), the averages of the two normalized data sets were calculated. Significantly correlated expression levels for mutant, normal and total huntingtin protein were also seen for different sets of RNA samples harvested and assayed at different times, supporting inter-set reproducibility. Therefore, the averages of four sets of data were used in statistical models (linear regression analysis) to test whether CAG repeat length could explain the variance present in the levels of expression of expanded, normal and total HTT mRNA. MLPA signals for the UTR SNPs were relatively smaller, and therefore, rs149 109 767 was primarily used for allele specific quantification of HTT mRNA.
Determination of total huntingtin protein levels by antibody-based MSD assays
Total huntingtin protein levels were determined in 28 of the LCLs by MSD assays (CHDI_HTT_039 assay) through BioFocus (30) . Briefly, cell pellets were lysed, and 15 mg of lysate were added to a micro-well plate coated with anti-huntingtin antibody 2B7 (capture antibody; raised against amino acids 1-17 of human huntingtin). Subsequently, anti-huntingtin detection antibody (biotinylated 4C9; raised against amino acids 51-71 of human huntingtin) was added for incubation. Then, streptavidin SULFO-TAG was added to generate signals for quantification by a microplate reader. The antibody pair 2B7 and 4C9 detects huntingtin protein regardless of the lengths of polyglutamine tracts and therefore is used to determine total huntingtin protein levels in a non-allele-specific manner.
Allele-specific huntingtin protein quantification using parallel reaction monitoring (PRM) assay
To evaluate the fragmentation pattern in the mass spectra of allele-specific huntingtin precursors, 5E (EEEWDEEEEEADAPAPS SPPTSPVNSR) and 6E (EEEWDEEEEEEADAPAPSSPPTSPVNSR) synthetic peptides were obtained from Bio-Synthesis (Lewisville, TX, USA). In addition to 5E and 6E peptides, three tryptic peptides derived from N-terminal (VLLGEEEALEDDSESR), middle (VLISQSTEDIVLSR) and C-terminal (SLLVVSDLFTER) regions of human huntingtin were selected to monitor total huntingtin protein level. To obtain endogenous huntingtin protein samples, total LCL extracts were prepared using M-PER (Thermo Scientific) supplemented with a Halt protease and phosphatase inhibitor cocktail (Pierce). Equal amounts of protein extract were subjected to SDS-PAGE gels, and subsequently the gels were stained with GelCode Blue Safe Protein Stain (Thermo Scientific). The upper area of the gel (around 350 kDa) that includes the endogenous huntingtin was cut from each lane and further processed for PRM analysis. The samples were reduced by 1 mM DTT for 30 min at 50 C and then alkylated by 5 mM iodoacetamide for 15 min in the dark at room temperature. Gel pieces were then digested by trypsin for separation by HPLC as described previously (43) . Eluted peptides were subjected to electrospray ionization and were entered into a Q Exactive hybrid mass spectrometer (Thermo Scientific). Data-dependent acquisitions (DDA) were performed according to an experiment where full MS scans from 300 to 1750 m/z were acquired at a resolution of 70 000 followed by 12 MS/MS scans acquired under Higher-energy C-trap dissociation (HCD) fragmentation at a resolution of 35 000 with an isolation width of 1.2 Da. For parallel reaction monitoring (PRM), five peptides were continuously monitored throughout the gradient using an isolation width of 2 Da followed by HCD fragmentation at a collision energy of 27% acquiring MS/MS spectra at a resolution of 35 000. The main PRM analysis was performed in technical triplicates of 28 HD LCLs. One cell line in the original panel of 29 LCLS that were analyzed by MLPA assay was dropped for PRM assays because of slow cell growth. Raw data files were processed with Proteome Discoverer (Thermo, version 1.4) prior to searching with Mascot Server (Matrix Science, version 2.4) against a Human database which contains both huntingtin variants. Search parameters utilized were fully tryptic with 2 missed cleavages, parent mass tolerances of 10 ppm and fragment mass tolerances of 0.05 Da. A fixed modification of carbamidomethyl cysteine and variable modifications of acetyl (protein N-term), pyro glutamic for N-term glutamine and oxidation of methionine were considered. Quantification of targeted peptides was accomplished through the Skyline software (University of Washington, version 2.4). Three fragment ion intensities that generated the most robust signals were extracted from each peptide and summed to determine the peptide abundance.
RNAseq analysis of HD neural progenitor cells
Induced pluripotent stem (iPS) cells were generated from local HD fibroblast collection (Harvard Stem Cell Institute iPS Core Facility, http://ipscore.hsci.harvard.edu/) and cultured on Matrigel-coated plates in mTeSRTM 1 media (STEMCELL Technologies). Human neural progenitor cells (NPC) were generated using STEMdiffTM NIM method (STEMCELL Technologies). Briefly, iPS cells were harvested using ACCUTASETM (STEMCELL Technologies) and re-suspended in STEMdiff neural induction media (supplemented with 10 mM Y-27632). Then, cells were plated in AggreWell800TM plates to induce neural aggregate formation (Embryoid Body). Neural induction media was changed daily for the next 4 days. On day 5, neural aggregates were harvested and plated onto PLO/Laminin-coated plates and cultured for additional 7 days. The neural rosettes formation and maturation was checked for next 7 days. The neural rosettes were selected on day 12 and plated onto Matrigel-coated plates for further neuronal progenitor cell population expansion in NPC media. For RNAseq analysis, total RNA was isolated by TRIzol (ThermoFisher Scientific). The integrity of the total isolated RNA was determined using Agilent 2100 Bioanalyzer, and samples with RNA integrity number (RIN value) of 8.5 and higher were selected for RNAseq library preparation. RNAseq libraries were prepared using a 96-well format optimized version of the strand-specific dUTP method (44, 45) . Briefly, magnetic oligo-dT beads were used to select mRNA, followed by DNase treatment for second strand synthesis using random hexamer in the presence of actinomycin D. A (dTTP replacing) dUTP incorporating second strand was generated followed by removal of second strand to retain the strandedness of the original transcripts. Subsequently, standard Illumina paired-end library preparation was carried out with added barcoded adaptors. The dUTPmarked strands were removed by adding uracil-specific exonuclease, followed by minimal PCR amplification and quantification. To control for extraneous variability in RNA expression and library preparation, we added 1 mL of a 1:10 dilution of Ambion ERCC RNA Control Spike-Ins (ThermoFisher Scientific) from one of two mixes (each containing the same 92 synthetic RNA standards of known concentration and sequence) to each library. Libraries were sequenced on a HiSEq 2000 to obtain 100-200 million total reads per sample. The raw sequence reads were quality checked using fastQC program. Sequence reads were aligned to the human genome using GSNAP. Cufflinks version 2.02 was used to generate fragments per kilobase per million reads (FPKMs). Only expression data of HTT were analyzed in this study, and a manuscript describing the full RNAseq data is in preparation.
Software package for data analysis
All data analyses were performed using Microsoft Excel or R (version, 3.0.2).
Supplementary Material
Supplementary Material is available at HMG online.
